Thanks. I guess it is all about how you view the finish line......even if losing 50% of gross income in costs, a 10% share could see profit of $650 000 000 each year (double the current market cap).
I believe the natural evolution of emerging cardiologists will see the popularity of the product increase. Using only my experience of the Australian situation, One cardiologist will supervise two trainees each year. Specialty medical training is generally 4 years, so each convert (who choses to use DURAVR) could be exposing 8 impending users of the product each 4 years.
its a wait and see game I guess.
AVR Price at posting:
$18.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)